Mice studies have revealed that loss of one of sirtuin (SIRT1) enzyme drives the formation of early prostate cancer (prostatic intraepithelial neoplasia, PIN).
SIRT1 can defend the cell against damage from free radicals. Researchers created a mouse model that lacked SIRT1. Normally SIRT1 proteins help activate a mitochondrial protein called SOD2, in turn activating those proteins to keep free-radical levels in check. When SIRT1 levels diminish, SOD2 is no longer effective at removing free radicals, allowing a dangerous build up in the cells, and leading to PIN.
Prostate Cancer: Treatment Options
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.
Advertisement
Lead researcher Dr. Richard Pestell said, "Using genetic deletion we found that SIRT1 normally restrains prostatic intraepithelial neoplasia in animals. Therefore too little SIRT1 may be involved in the cellular processes that starts human prostate cancer. As we had shown that gene therapy based re expression of SIRT1 can block human prostate cancer tumor growth, and SIRT1 is an enzyme which can be targeted, this may be an important new target for prostate cancer prevention."
The research is published online in 'The American Journal of Pathology'.
Source: Medindia
Source: Medindia
![Prostate Specific Antigen [PSA]](https://www.medindia.net/images/patientinfo/300x250/prostate-specific-antigen.jpg "Prostate Specific Antigen [PSA]")
Prostate Specific Antigen [PSA]
PSA blood test is specific to prostate gland but not necessarily a cancer specific test but is commonly used to diagnose prostate cancer.
Advertisement
 Prostate Cancer ScreeningPSA (Prostate Specific Antigen) test and Digital Rectal Examination are two tests that allow detection of prostate cancer at early stages. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The blood test pinpointed 13 proteins capable of distinguishing between early and late stages of pancreatic cancer.
A fatty acid present in dairy products, beef, and lamb called trans-vaccenic acid enhances immune cells' capacity to combat cancers.
Trametinib plus dabrafenib combined therapy demonstrated a clear therapeutic benefit in children with BRAF-mutated low- and high-grade gliomas.
Examining breast cancer occurrence and stages reveals disparities in urban versus rural rates, influenced by environmental conditions and the stage of the disease.
Polymerases theta and delta assist in the development of new cancer drugs known as polymerase theta inhibitors, currently undergoing clinical trials.